Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetirizine + famotidine
- Development stage
- Phase 4
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy that blocks both histamine-1 (H1) and histamine-2 (H2) receptors. Cetirizine is an antihistamine that primarily affects the respiratory system and skin by blocking H1 receptors, while famotidine blocks gastric H2 receptors to decrease stomach acid production. This dual-histamine receptor blockade has been studied for various conditions including COVID-19, interstitial cystitis/bladder pain syndrome, and allergic conditions. The combination has shown beneficial effects in reducing inflammation and cytokine release.
- Other names
- Antihistamine combination therapyH1 and H2 antihistamine therapyH-1 and H2 antihistamine therapyH 1 and H2 antihistamine therapy
02
Targets
HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on cetirizine + famotidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetirizine + famotidine.